Alvotech settles with J&J to launch Stelara biosimilar in Europe, Canada

,

Alvotech settles with J&J to launch Stelara biosimilar in Europe, Canada

Feb 15 (Reuters) – Alvotech (ALVO.O) said on Thursday it has reached settlement agreements with Johnson & Johnson (JNJ.N) for launching a biosimilar of the pharmaceutical giant’s blockbuster psoriasis drug Stelara in Japan, Canada, and Europe this year.

The deals allow Alvotech’s biosimilar, or near copies of a biological drug, to enter the Canadian market in the first quarter of this year and Japan in May. Entry to the first European markets is expected after late July.
 
Stelara has been J&J’s top-selling drug since 2019, but its key patents began to expire last year.
 
Alvotech said its marketing partner in Japan, Fuji Pharma (4554.T) already has authorization for the drug and it will be marketed as Ustekinumab BS (F) in the country, while the biosimilar will be sold by Alvotech’s partner JAMP Pharma in Canada.
 
STADA Arzneimittel will start selling the biosimilar under the name Uzpruvo from July in some countries that are part of the European Economic Area.